Multitarget-based screening from phytoactive compounds of fighting toward severe acute respiratory syndrome coronavirus-2.

OBJECTIVES

The recent global coronavirus disease 2019 (COVID-19) pandemic, resulting from infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), can cause severe and fatal pneumonia along with other life-threatening complications.

MATERIALS AND METHODS

The rare and limited accessibility of approved therapeutic agents or vaccines is of great distress. Swiftly working on designing and identifying inhibitors against all possible viral key protein targets, seven key SARS-CoV-2 viral enzymes were selected as targets, particularly in the action on the virus-entry, viral replication, and immune evasion of COVID-19. Papain-like protease, main protease, RNA-dependent RNA polymerase, endoribonuclease (nsp15), receptor-binding domain-angiotensin-converting enzyme 2, transmembrane serine protease 2 (TMPRSS2), and 2'- O-ribose methyltransferase (2'MTase), which were subjected to an unbiased screening against 22 small molecules originating from concomitantly with Remdesivir, Nirmatrelvir, and Molnupiravir were approved by Food and Drug Administration as repurposing drugs against SARS-CoV-2 invasion.

RESULTS

The results showed that natural bioactive compounds containing α-Tocopheryolquinone, 6β-Hydroxystigmast-4-en-3-one, Squalene, Rutin and Quercetin have a high binding affinity with seven selected viral protein targets concurrently with the preference of absorption, distribution, metabolism, excretion, and toxicity and drug-likeness.

CONCLUSION

This study provides potential phytoactive compounds from . through multi-target screen with molecular dynamic simulation for combating COVID-19 pandemics that need further experimental validation to confirm the prospective efficacy.